MRAI Marpai, Inc.
Services-Misc Health & Allied Services, NEC · OTC · SEC CIK 1844392 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.8%
TTM net income YoY-37.9%
TTM EPS YoY-6.2%
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—
Margins
Gross margin25.0%
Operating margin-78.4%
Net margin-98.0%
FCF margin—
EBITDA margin-77.7%
Returns
ROE—
ROA-141.5%
ROIC (approx.)—
Asset turnover1.44x
Leverage & solvency
Liabilities / assets375.3%
Debt / equity—
Current ratio0.65x
Interest coverage-3.64x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $18.10M | $28.17M |
| Cost of revenue | $13.32M | $19.07M |
| Gross profit | $4.78M | $9.11M |
| R&D expense | $7,000 | $29,000 |
| SG&A expense | $11.14M | $12.83M |
| Operating income | -$13.55M | -$22.09M |
| Interest expense | $3.23M | $2.71M |
| Pretax income | -$16.56M | -$23.28M |
| Income tax | — | -$1.19M |
| Net income | -$16.56M | -$22.09M |
| EBITDA | -$13.17M | -$19.83M |
| EPS (basic) | -0.95 | -1.92 |
| EPS (diluted) | -0.95 | -1.92 |
| Weighted avg. shares (diluted) | 17.37M | 11.51M |
| Balance sheet | ||
| Cash & equivalents | $133,000 | $9.23M |
| Receivables | $697,000 | $837,000 |
| Current assets | $10.34M | $11.90M |
| PP&E, net | $0 | $0 |
| Intangibles | $60,000 | $441,000 |
| Total assets | $10.90M | $12.88M |
| Current liabilities | $25.69M | $18.98M |
| Short-term debt | $8.00M | $6.10M |
| Long-term debt | $19.40M | $17.79M |
| Total debt | $27.40M | $23.89M |
| Total liabilities | $43.47M | $40.59M |
| Shareholders' equity | -$32.56M | -$27.71M |
| Net debt | $27.27M | $14.66M |
| Shares outstanding | 24.04M | 14.24M |
| Cash flow statement | ||
| Operating cash flow | -$7.45M | -$15.16M |
| Investing cash flow | $500,000 | $227,000 |
| Financing cash flow | $6.67M | $10.67M |
| Depreciation & amortization | $381,000 | $2.26M |
| Stock-based compensation | $3.61M | $3.16M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.